• MC38-hPD-L1-LZ cells express homogeneous high levels of human PD-L1 and ZsGreen

  Expression analysis by flow cytometry. hPD-L1 is expressed in MC38-hPD-L1 (left panel) and MC38-hPD-L1-LZ cells (right panel). MC38-hPD-L1-LZ cells also express ZsGreen.

   

  

• MC38-hPD-L1-LZ cells form tumors in vivo, and are detectable by luminescence imaging

  Wild-type C57BL/6 mice were injected (s.c.) with 1x10⁵ MC38 or MC38-hPD-L1-LZ cells. (A) Tumor growth was measured every 3 days. Tumor size (mm³) = (width² x length)/2. 6 mice were injected per group, with 5 mice developing tumors for MC38 and MC38-hPD-L1-LZ injected groups. (B) Mice received injections (i.p) of D-Luciferin (150mg/kg) and were imaged 15 minutes later under isoflurane anaesthesia on an IVIS Lumina II imager. Note that tumors can be detected by luminescence imaging before they are palpable (D8).

  

  更多详细数据请联系我们：联系我们 - 基锘威 - genOway (my3w.com)

   

Commentaries

1. Development of a new hSIRPα-specific radiotracer for non-invasive PET imaging using genOway’s double humanized hCD47/hSIRPα mouse and MC38-hPD-L1-hCD47-LZ cell line
2. CCX559 is a potent, orally-administered small molecule PD-L1 inhibitor that induces anti-tumor immunity
3. A new promising family of small molecules regulating the PD-L1/PD-1 signaling pathway
4. Improving in vitro models: the coming of age of organoids
5. iPS technology: Four factors that will change the world… some day

Scientific articles

1. Two birds with one stone: human SIRPα nanobodies for functional modulation and in vivo imaging of myeloid cells
2. CCX559 is a potent, orally-administered small molecule PD-L1 inhibitor that induces anti-tumor immunity
3. ERα-36 regulates progesterone receptor activity in breast cancer
4. T-cells expressing a chimeric-PD1-Dap10-CD3zeta receptor reduce tumour burden in multiple murine syngeneic models of solid cancer
5. Tumor Vessel Normalization, Immunostimulatory Reprogramming, and Improved Survival in Glioblastoma with Combined Inhibition of PD-1, Angiopoietin-2, and VEGF
6. SDHA gain-of-function engages inflammatory mitochondrial retrograde signaling via KEAP1-Nrf2